A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions
Autoimmune Diseases
Interventions
DRUG

GSK2982772 capsule

GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.

DRUG

Placebo capsule

Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY